Table 1. Clinical Baseline characteristics of patients.

Age (years)		51 ± 15
Women		78/142 (54.9%)
Largest diameter of tumour (mm)		23.1±12.4
Second surgery*		19/142 (13.4%)
Radiotherapy		0
Medical treatment
ST adenomas		26/36 (72.2%)
		18 SSa
		3 SSa + DA
		2 SSa + Peg
		2 DA
		1 Peg
		8 without treatment
		2 unknown
TT adenomas		2/2 (100%)
		1 SSa
		1 carbimazole
CT adenomas		11/21 (52.4%)
		6 KET
		4 KET + DA
		1 DA
		9 without treatment
		1 unknown
LT adenomas		8/9 (88.9%)
		8 DA
		1 unknown
NFPA		10/74 (13.5%)
		10 DA
		61 without treatment
		3 unknown
Invasiveness	Extension (Hardy)
Non Invasive	Intrasellar (I-II)	39/137 (28.5%)
	Extrasellar (III)	44/137 (32.1%)
Invasive	Invasive (IV)	54/137 (39.4%)
Unknown extension		5/142

Data shown as mean ± SD or n/total (%).ST: somatotroph, TT: thyrotroph adenomas, CT: corticotroph, LT: lactotroph adenomas, NFPA: non-functioning pituitary adenomas, SSa: somatostatin analogs, DA: dopamine agonist, Peg: Pegvisomant, KET: Ketoconazole.